Appel Alzheimer’s Disease Research Institute

Weill Cornell Medicine scientists have developed an innovative human neuron model that robustly simulates the spread of tau protein aggregates in the brain—a process that drives cognitive decline in Alzheimer's disease and frontotemporal dementia. 

The 11th annual Appel Alzheimer's Disease Research Institute Symposium brought together leading scientists and clinicians in the field to present the latest advances in understanding Alzheimer’s and related neurodegenerative diseases. 

Targeting part of an antiviral pathway triggered by the accumulation of a key pathogen shared in Alzheimer’s disease and frontotemporal dementia may one day offer a new therapeutic approach to deterring or delaying cognitive decline.

The 10th annual Appel Alzheimer's Disease Research Institute Symposium brought fascinating reports of progress in understanding Alzheimer’s and related neurodegenerative diseases.

Aggregates of the protein alpha-synuclein spread in the brains of people with Parkinson’s disease through a cellular waste-ejection process, suggests a new study led by Weill Cornell Medicine researchers.

The discovery of how to shift damaged brain cells from a diseased state into a healthy one poses a new potential path to treating Alzheimer’s and other forms of dementia.

Inhibiting an important signaling pathway in brain-resident immune cells may calm brain inflammation and thereby slow the disease process in Alzheimer’s and some other neurodegenerative diseases, suggests a study by Weill Cornell Medicine investigators.

By mapping all the protein interactions of a dementia-linked protein in the brain called Tau, a team of Weill Cornell Medicine investigators has created a road map for identifying potential new treatment targets for Alzheimer’s disease and related dementia.

A gene mutation linked to Alzheimer’s disease alters a signaling pathway in certain immune cells of individuals with the disease, according to a new study by scientists at Weill Cornell Medicine.

Some of the latest research discoveries in neurodegenerative disease and their potential therapeutic applications were featured at the ninth annual Appel Alzheimer's Disease Research Institute Symposium, held remotely on Nov. 9. 

Investigators on the forefront of research into neurodegenerative disorders shared some of their latest discoveries and possible implications for treatment at the eighth annual Appel Alzheimer's Disease Research Institute Symposium, held remotely on Oct. 14.

In the roughly 100 years since Alois Alzheimer first described the devastating neurodegenerative disease that now bears his name, scientists have developed an increasingly sophisticated understanding of the brain. 

A novel mechanism that regulates activity in the brain, discovered by Weill Cornell Medicine investigators, may help explain the origins of one common type of dementia.

Weill Cornell Medicine has experienced dynamic growth in its research enterprise over the past five years, an achievement that underscores the institution’s mission to provide patients with the most advanced treatments and therapies.

World experts in neurodegenerative diseases gathered at Weill Cornell Medicine Sept. 25 for the sixth annual Appel Alzheimer’s Disease Research Institute Symposium, sponsored by the Appel Institute and its home department, the Feil Family Brain and Mind Research Institute. Every year, the symposium highlights the latest discoveries in the field, as researchers work their way toward a cure.

Dr. Li Gan, a neuroscientist internationally acclaimed for her research into neurodegenerative diseases, has been appointed director of the Helen and Robert Appel Alzheimer’s Disease Research Institute at Weill Cornell Medicine, effective July 1.

Advances in scientific innovation are leading to powerful discoveries about Alzheimer’s and neurodegenerative diseases, sparking hope for the development of new treatment and therapies for the conditions.